Company Profiles

driven by the PitchBook Platform

Dynamix Pharmaceuticals

Dynamix Pharmaceuticals
2009 FOUNDED
OOB STATUS
11-50 EMPLOYEES
Out of Business LATEST DEAL TYPE
$10M TOTAL AMOUNT RAISED
Description

Developer of novel, targeted, small-molecule drugs created to treat cancer and autoimmune disorders. The company's small-molecule drugs intervene with the metabolism of cancer cells and selectively target specific cellular signaling pathways, also known as Type II kinase inhibitors, enabling physicians to treat urgent and unmet medical needs in cancer and autoimmune disorders.

Website:
Ownership Status
Out of Business
Financing Status
Formerly VC-Backed
Primary Industry
Drug Discovery
Primary Office
Rehovot Business Park
Third level, Suite 308, 13 Gad Feinstein Road
Rehovot 76385
Israel
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Dynamix Pharmaceuticals’s full profile, request a free trial.

Dynamix Pharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business $10M Completed Out of Business
1. Early Stage VC (Series A) 16-Feb-2009 0000 0000 Completed Startup
To view this company’s complete deal history including valuation and funding request access »

Dynamix Pharmaceuticals Executive Team (2)

Name Title Board
Seat
Contact
Info
Oren Becker Ph.D Founder, President, and Chief Executive Officer
Yossi Bar-On Chief Financial Officer